Early access
Sign in
Taking people in United KingdomPhase 2/3

PF-07275315 compared with placebo in adults with moderate to severe COPD

Tests PF-07275315 given as shots in adults with moderate to severe COPD.

Key facts

Who runs it
Pfizer
Where
Bradford, Chertsey, Glasgow, Leicester, London, Manchester, and North Shields, United KingdomSee the 8 sitesAlso in 18 other countries, 192 sites
Registry title
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status
Recruiting
Phase
Phase 2/3
People taking part
1,156 people, planned
Started
11 Feb 2026
Expected to end
16 Jan 2031
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PF-07275315 dose 1
  • PF-07275315-dose 2
  • Placebo
  • PF-07275315-dose 3
Record updated
22 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 35 to 80 with moderate-to-severe COPD who have had at least 2 moderate or severe flare-ups in the past 12 months.

Age
35 to 80 years
Sex
All sexes can join.
Disease stage
Moderate-to-severe COPD diagnosed at least 12 months ago, with post-bronchodilator FEV1/FVC below 70% and FEV1 % predicted below 70% but at least 30%.
Earlier treatment
Must have taken standard triple therapy (LABA + LAMA + ICS) continuously for at least 6 months, at a stable dose for at least 3 months. Must have had at least 2 moderate or severe COPD exacerbations in the last 12 months.

Main reasons for not taking part

  • Significant lung disease other than COPD
  • Continuous oxygen treatment at more than 4.0 liters per minute by nasal cannula or equivalent
  • Resting SpO2 below 88% while breathing room air (or on usual oxygen level)
  • Clinically significant heart disease, severe left heart failure, or cor pulmonale

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition)
  • Spirometry values (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] less than [<] 70 percent (%) and post-bronchodilator FEV1 % predicted <70%, but greater than equal to 30%)
  • Continuous treatment with standard of care triple therapy of LABA + LAMA + ICS for ≥ 6 months prior to Screening Visit 1 and at a stable dose for ≥3 months
  • Documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening

Who cannot take part

  • Requirement for continuous chronic treatment with oxygen at >4.0 liters / minute by nasal cannula or equivalent
  • Significant pulmonary disease other than COPD
  • Clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor pulmonale
  • Hypoxemia with a resting SpO2 <88% while breathing ambient air (or on the participant's usual level of oxygen supplementation)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 35 and 80 years old?

Where in United Kingdom

Also in 18 other countries, 192 sites

  • Bradford Royal InfirmaryBradford, United KingdomTaking people
  • Ashford and St Peter's Hospital NHS Foundation TrustChertsey, United KingdomTaking people
  • Glasgow Royal InfirmaryGlasgow, United KingdomTaking people
  • The Glenfield HospitalLeicester, United KingdomTaking people
  • Guy's & St Thomas' NHS Foundation TrustLondon, United KingdomNot yet recruiting
  • Queen Anne Street Medical CentreLondon, United KingdomTaking people
  • Wythenshawe HospitalManchester, United KingdomTaking people
  • North Tyneside General HospitalNorth Shields, United KingdomNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.

Read full original descriptionShow less

This study is seeking participants who:

* Are 35 to 80 years old * Have had moderate-to-severe COPD for at least 12 months * Have a documented history of at least 2 moderate or severe exacerbations within the last 12 months * Have been continuously taking their regular maintenance treatment(s) for COPD over at least 6 months at a stable dose for 3 months

All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.

PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 24 weeks for the Phase 2 part and 52 weeks for the Phase 3 part. We will compare the results of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective.

Participants who will be involved in the Phase 2 part of the study for about 40 weeks. During this time, they will have 11 visits at the study clinic.

Participants who will be involved in the Phase 3 part of the study for about 68 weeks. During this time, they will have 18 visits at the study clinic.

The 5 groups in the trial

  • Phase 3 Treatment Arm ATreatment being tested

    Treatment: PF-07275315-dose 3

  • Phase 2 Treatment Arm BTreatment being tested

    Treatment: PF-07275315-dose 2

  • Phase 2 Treatment Arm ATreatment being tested

    Treatment: PF-07275315 dose 1

  • Phase 3 Treatment Arm BPlacebo, for comparison

    Treatment: Placebo

  • Phase 2 Treatment Arm CPlacebo, for comparison

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Plain-language title
PF-07275315 compared with placebo in adults with moderate to severe COPDGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07363694, who can take part
Record updated
22 October 2026